These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - Maze Therapeutics ( NASDAQ:MAZE )
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Maze Therapeutics, Inc. ( NASDAQ:MAZE ) , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot ...
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Maze Therapeutics, Inc. ( Nasdaq: MAZE ) , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot ...
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
INCY vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte ( INCY Quick QuoteINCY - ) and argenex SE ( ARGX Quick QuoteARGX - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
China Medical System ( 867.HK; 8A8.SG ) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
China Medical System (867.HK. 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication ...
China Medical System ( 867.HK; 8A8.SG ) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
SHENZHEN, CHINA, Sept. 28, 2025 ( GLOBE NEWSWIRE ) -- China Medical System Holdings Limited ( "CMS" ) is pleased to announce that its subsidiaries, Dermavon Holdings Limited ( "Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on ...
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
MONTREAL, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. ( TSX:GUD ) ( "Knight" or "the Company" ) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine's ranking of Canada's Top Growing Companies.
Strength Seen in Oculis Holding AG ( OCS ) : Can Its 6.7% Jump Turn into More Strength?
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market - Apollo Asset Management ( NYSE:APO ) , American Express ( NYSE:AXP )
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. Cramer, the host of CNBC's "Mad Money," highlighted a range of stocks from different sectors that he believes are ...
Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher
Jim Cramer says there are still bargains in the S&P 500, highlighting names like T-Mobile, Dollar Tree, Caterpillar and Dell as growth at value.
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children - Incyte ( NASDAQ:INCY )
The U.S.
Syndax's Revuforj® ( revumenib ) Included in NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® ( NCCN® ) Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) ...
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
LH Stock Rises on Acquisition of BioReference Health's Select Assets
Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Why Is TG Therapeutics ( TGTX ) Up 4.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte ( INCY ) Up 9.4% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
S&P 500 Losers: 22 Stocks In Negative Zone, One Got The Boot - SPDR S&P 500 ( ARCA:SPY )
22 stocks in the S&P 500 Index are down over the last 10 years based on total returns. A look at the list, which includes one stock exiting the S&P 500 Index. The market is reacting to Powell's speech. Learn how to time your next move. Details here →
Is it the Right Time to Hold Labcorp Stock in Your Portfolio?
LH witnesses growth in specialty testing and strategic acquisitions, but macro and currency headwinds remain a concern.
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Knight Therapeutics Reports Second Quarter 2025 Results
Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. GUD ( "Knight" or "the Company" ) , a pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its ...
Xencor ( XNCR ) Q2 Revenue Jumps 82%
Xencor ( NASDAQ:XNCR ) , a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company's GAAP revenue of $43.6 million exceeded analyst estimates by $21.0 million and Revenue ( GAAP ) increased ...
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
Syndax ( SNDX ) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals ( NASDAQ:SNDX ) , a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its substantial GAAP revenue growth, driven primarily by commercial traction for its newly launched ...
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Turning Point Brands ( NYSE:TPB ) , Incyte ( NASDAQ:INCY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Gerald Pascarelli initiated coverage on Turning Point Brands, Inc.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® ( tafasitamab ) for Follicular Lymphoma in Brazil
MONTREAL, July 31, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian ...
Why Incyte ( INCY ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Incyte ( NASDAQ:INCY )
Incyte Q2 revenue rose 16% to $1.22B, beating estimates; EPS at $1.57 vs. loss of $1.82 YoY Jakafi guidance raised to $3-$3.05 billion for 2025; other oncology products also see upward revisions Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday - Rich Sparkle Holdings ( NASDAQ:ANPA ) , Amkor Tech ( NASDAQ:AMKR )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Sanmina Corporation SANM rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.
Incyte ( INCY ) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Labcorp Posts 9.5 Percent Gain in Q2
Laboratory Corporation of America ( NYSE:LH ) , a global leader in diagnostics and drug development, reported results for Q2 2025 on July 24, 2025. The earnings release highlighted strong GAAP revenue growth that beat consensus estimates, adjusted earnings per share ( non-GAAP ) that outpaced ...
Why Is Testing Giant Labcorp Stock Surging On Thursday? - Labcorp Hldgs ( NYSE:LH )
Q2 adjusted EPS rose to $4.35 from $3.94, beating the $4.17 estimate. FY25 earnings guidance raised to $16.05-$16.50 vs prior range of $15.70-$16.40. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this Wednesday. Secure access here.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Labcorp ( LH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Need a quote from one of our analysts? Email [email protected] ( NYSE:LH ) reported double-digit top-line growth and margin expansion for fiscal Q2 2025, raising full-year 2025 guidance and attributing performance to continued strength in diagnostics and momentum in ...
Alnylam Pharmaceuticals ( ALNY ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Incyte ( INCY ) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is BrightSpring Health Services, Inc. ( BTSG ) Outperforming Other Medical Stocks This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Incyte (INCY) have performed compared to their sector so far this year.
INCY or TECH: Which Is the Better Value Stock Right Now?
INCY vs. TECH: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0 - Incyte ( NASDAQ:INCY )
Highlighted on June 30, it was unveiled in an SEC filing that Meury, Chief Executive Officer at Incyte INCY, executed a significant transaction involving the exercise of company stock options. What Happened: A notable Form 4 filing on Monday with the U.S.
